Investor Presentaiton

9MFY22 Highlights Revenues *1,072.8 Cr 2.6% YoY EBITDA 195.2 Cr (20.1)% YoY (510) Bps PAT 157.2 Cr (1.2)% YoY (90) Bps EPS 3.82 (0.3)% YoY ☐ Financial Highlights Operating Revenue was 1,072.8 cr.; growth of 2.6% as compared to 1,046.0 Cr. in 9MFY21 EBITDA at 195.2 cr. as compared to 244.2 cr.in 9MFY21 EBITDA margins at 18.2% in 9MFY22 as against 23.3% in 9MFY21 ■ PAT stood at 157.2 Cr. as compared to 159.2 Cr. in 9MFY21 ☐ ■ EPS for 9MFY22 was 3.82 compared to 3.83 in 9MFY21 ©2021 - Marksans Pharma Limited, All Rights Reserved. Business Highlights ■ R&D spend of 21.7 cr. at 2.0% of sales in 9MFY22 Capex for 9MFY22 at 32.8 cr. ■ EBITDA margin reduction due to increased input & freight costs and incremental R&D expenses ■ Better product mix, lower depreciation, finance cost and reduced tax outflow meant a marginal reduction in PAT New Launches Launched new products: ■ Cetirizine Hydrochloride Tablets 5 mg and 10mg for perennial allergic rhinitis treatment in US ■ Acetaminophen Extended-Release Tablets USP, 650 mg (OTC) in US Fluoxetine in US ■ Loperamide 2mg Hard Capsules in UK 5

View entire presentation